United Therapeutics Corporation (NASDAQ: UTHR) today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin® (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. Remodulin will be sold in Japan under the brand name Treprost™ by Mochida Pharmaceutical Co., Ltd., under an exclusive distribution agreement with United Therapeutics.
"We are grateful for Mochida's diligent work in obtaining this approval in Japan," said Yu-Lun Lin, United Therapeutics' Associate Vice President and Managing Director, UTAsia. "We look forward to Mochida's launch of Treprost and to bringing this new therapeutic option to the PAH community in Japan."
New study reveals ketogenic diet's role in combating obesity